Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1713999

registered interest
date	25/04/2024
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Graduates
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when they plan to the respond to the letter from Professor Brian Bell of the Migration Advisory Committee requesting data for a rapid review of the Graduate Route.
tabling member printed	Baroness Northover
uin	HL4106
answer	answer is ministerial correction date of answer 10/05/2024 answer text <p>We provided the requested data to the Migration Advisory Committee by 26 March 2024.</p> answering member printed Lord Sharpe of Epsom question first answered 10/05/2024 11:18:52 answering member 4888 label Biography information for Lord Sharpe of Epsom
tabling member	2539 label Biography information for Baroness Northover

1688054

registered interest
date	06/02/2024
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Developing Countries: Genito-urinary Medicine
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to achieve universal access to sexual and reproductive health and rights as per Sustainable Development Goal target 5.6.
tabling member printed	Baroness Northover
uin	HL2253
answer	answer is ministerial correction date of answer 15/02/2024 answer text <p>The White Paper on International Development reaffirmed the UK's commitment to deploy policy and investment to advance and strongly defend universal access to comprehensive Sexual and Reproductive Health and Rights (SRHR) in line with Sustainable Development Goal target 5.6.</p><p>The UK Government is committed to driving progress and demonstrating leadership on SRHR globally as a major donor, through our diplomatic network and in collaboration with partners. For example, the UNFPA Supplies Partnership averted 8 million unintended pregnancies, 2.2 million unsafe abortion and 170,000 maternal and child deaths in 2022, with the UK as their largest donor. The Women's Integrated Sexual Health (WISH) Programme supported 9.5 million women to use modern methods of contraception and averted over 45,000 maternal deaths, 5 million unsafe abortions and over 16 million unintended pregnancies from the programme's inception to 2021. In May 2023, the UK joined other G7 leaders in re-asserting the critical role of comprehensive SRHR in our efforts to achieve gender equality, explicitly recognising the need for access to safe and legal abortion as well as post abortion care.</p> answering member printed Lord Benyon question first answered 15/02/2024 10:46:54 answering member 1547 label Biography information for Lord Benyon
tabling member	2539 label Biography information for Baroness Northover

1685362

registered interest
date	26/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives: Taxation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to their policy paper 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement, published on 20 November 2023, what assessment they have made of any potential detrimental impact on women's health if the tax on the contraceptive implant Nexplanon is increased to 35 per cent.
tabling member printed	Baroness Northover
uin	HL1963
answer	answer is ministerial correction date of answer 01/02/2024 answer text <p>The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) introduces a new way of controlling the cost of older medicines that is explicitly pro-innovation and pro-competition. We do not anticipate this resulting in a detrimental impact on women's health or, given the available mitigations, on the supply of medicines.</p><p>Medicines for women’s health will be subject to the VPAG in the same way that all other medicines are. They will be subject to the top up payment percentage only when they have not seen a sufficient price decline since the active substance lost market exclusivity.</p><p>In exceptional circumstances, where a product would otherwise be uneconomic to supply, companies can apply to the Department for a price increase or for an adjustment to the top up payment percentage that applies.</p> answering member printed Lord Markham question first answered 01/02/2024 12:21:09 answering member 4948 label Biography information for Lord Markham
tabling member	2539 label Biography information for Baroness Northover